Analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on Shattuck Labs (STTK – Research Report), retaining the price target of $4.00.
Faisal Khurshid has given his Buy rating due to a combination of factors including Shattuck Labs’ strategic focus on inflammatory bowel disease (IBD) and the promising potential of their lead program, SL-325. This program represents a novel approach that could enhance existing TL1A targeting treatments, which have already shown clinical validation. The company’s recent pivot to IBD is seen as an underappreciated opportunity, and the initiation of Phase 1 trials for SL-325 in the third quarter of 2025 is a significant milestone that could attract investor interest.
Furthermore, Shattuck Labs has shared preclinical and translational data suggesting that targeting DR3 could be both safe and effective. The planned Phase 1 trial will assess pharmacokinetics, pharmacodynamics, safety, and biomarker data, providing insights into the feasibility of targeting DR3. The trial aims to establish the appropriate dose and schedule for subsequent phases, with full data expected by mid-2026. This progress, along with the company’s efforts to demonstrate minimal cytokine impact and effective TL1A inhibition, supports the potential for a successful turnaround and growth story for Shattuck Labs.
STTK’s price has also changed dramatically for the past six months – from $3.870 to $1.140, which is a -70.54% drop .